The company will soon let patients order a personal genetic test online through a genetic counselor or physician, Invitae CEO Sean George said last week at the J.P. Morgan Healthcare Conference.

Invitae CEO Ken Knight takes the questions and pushes out the answers on the genetic testing company's plans. The $100 genome is here, East Bay company claims as it exits stealth Clinical trial ...

Invitae is a growth leader in genetic testing. The company is growing at full speed, and it has enormous room for expansion going forward. Lack of profitability and share dilution are the main ...

The company, which has aggressively bought companies to expand its genetic testing strategy, plans to consolidate lab and office space and narrow international operations as it cuts about a third ...

Invitae is building a platform to make genetic tests simple and accessible to a wide array of people. The Global Genetic Testing Market size is expected to reach $16.9 billion by 2025. By using a ...

Invitae’s business operations are heading to a new home. Under a bankruptcy auction, Labcorp was selected as the winning bidder for the firm’s genetic testing services, digital health ...

Rather than picking a single genetic variant to test at a cost of more than $1,000 each, Invitae is building a testing platform to identify several thousand genetic variants at a cost below $250 ...

Invitae CEO Sean George joins Yahoo Finance's on the move to talk about how Invitae is bringing genetic testing and information into mainstream discussions. JULIE HYMAN: I'm watching shares of ...

Friday, the FDA granted de novo approval for Invitae Corporation's NVTA Common Hereditary Cancers Panel, an in vitro diagnostic test that can help detect hundreds of genetic variants associated ...

Invitae shares have dropped more than 60% this year. Invitae (NVTA) recently announced news that made its shares pop. The genetic testing company won a regulatory nod for a first-of-its-kind test ...